VK2809 (formerly known as MB07811) is a thyromimetic prodrug whose active form is selective for the THR-β isoform. It is being developed by Viking Therapeutics in a phase II trial for the treatment of nonalcoholic steatohepatitis[1][2] and is also being investigated for glycogen storage disease type Ia.[3]
^"VK2809". Viking Therapeutics. Retrieved 15 September 2023.
^Alkhouri, Naim (1 February 2020). "Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196)". Expert Opinion on Investigational Drugs. 29 (2): 99–101. doi:10.1080/13543784.2020.1708899. ISSN 1354-3784.
^Zhou, Jin; Waskowicz, Lauren R.; Lim, Andrea; Liao, Xiao-Hui; Lian, Brian; Masamune, Hiroko; Refetoff, Samuel; Tran, Brian; Koeberl, Dwight D.; Yen, Paul M. (1 August 2019). "A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia". Thyroid. 29 (8): 1158–1167. doi:10.1089/thy.2019.0007. ISSN 1050-7256. PMC 6707038. PMID 31337282.
VK2809 (formerly known as MB07811) is a thyromimetic prodrug whose active form is selective for the THR-β isoform. It is being developed by Viking Therapeutics...
selective for TRβ—including eprotirome, sobetirome, resmetirom, and the prodrug VK2809—have been investigated for the treatment of non-alcoholic fatty liver disease...
stealing Viking's trade secrets to develop ASC41 which is allegedly similar to VK2809. Fröhlich, Eleonore; Wahl, Richard (4 August 2022). "Insight into Potential...